In recent years, Glucagon-Like Peptide-1 (GLP-1) receptor agonists have gained popularity as a key medication in patients' diabetes management regimens, particularly in those patients with comorbid conditions like chronic kidney disease and cardiovascular disease [3]. This evidence concerns the gene GCG and cardiovascular disorder.